S 4439 116th Congress Senate Health Business records Cardiovascular and respiratory health Civil actions and liability Corporate finance and management Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Government information and archives Health programs administration and funding Health promotion and preventive care Immunology and vaccination Infectious and parasitic diseases Inflation and prices Intellectual property Licensing and registrations Manufacturing Medical research Medical tests and diagnostic methods Performance measurement Prescription drugs

MMAPPP Act of 2020

Introduced: August 5, 2020 Introduced by: Smith, Tina Democratic · Minnesota See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Aug 5, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Aug 5, 2020

Introduced in Senate

Plain-English summary Congressional Research Service

Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020

This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.

With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.

The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.

If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.

What's happening now August 5, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Committees of jurisdiction 1